Literature DB >> 19467021

Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials.

Jian Shi1, Zhi Li, Xin Zeng, Yong Lin, Wei-Fen Xie.   

Abstract

AIMS: The effect of ursodeoxycholic acid (UDCA) treatment on survival and liver histological progression of primary sclerosing cholangitis (PSC) remains uncertain. The aim of the present study was to evaluate the effect and safety of UDCA in PSC.
METHODS: Electronic databases including Medline, Embase, Cochrane controlled trials register, Web of Science and PubMed (updated to January 2009) and manual bibliographical searches were carried out. A meta-analysis of all randomized controlled trials (RCT) comparing UDCA with placebo or no treatment was carried out.
RESULTS: Eight RCT including 465 patients were assessed. UDCA could significantly improve liver biochemistry, but had no effect on pruritus and fatigue. Meta-analysis of the included RCT showed UDCA had no significant effect on the incidence of death, liver transplantation, and death and/or liver transplantation. However, a significant difference for the incidence of histological improvement was found between the two groups (odds ratio [OR], 9.19; 95% CI: 0.98, 86.15; P = 0.05). Meta-analysis also indicated a reduction trend of histological deterioration and an improvement trend of cholangiographic changes. These trends were constant in the sensitivity analyses.
CONCLUSION: The meta-analysis found that UDCA can improve liver biochemistry and there is a trend towards improvement in liver histology and cholangiography, but has no effect on survival free of transplantation.

Entities:  

Year:  2009        PMID: 19467021     DOI: 10.1111/j.1872-034X.2009.00527.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  14 in total

1.  Hepatobiliary disease associated with hypereosinophilia: a report of two patients and a review of the literature.

Authors:  L M Morgan-Rowe; M Pericleous; T V Luong; J S Dooley; A K Burroughs
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

2.  Sclerosing cholangitis: pediatric perspective.

Authors:  Nanda Kerkar; Tamir Miloh
Journal:  Curr Gastroenterol Rep       Date:  2010-06

Review 3.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 4.  Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.

Authors:  Bjarte Fosby; Tom H Karlsen; Espen Melum
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

5.  Remnant gastropathy due to bile reflux after Roux-en-Y gastric bypass: a unique cause of abdominal pain and successful treatment with ursodiol.

Authors:  Nitin Kumar; Christopher C Thompson
Journal:  Surg Endosc       Date:  2017-08-10       Impact factor: 4.584

Review 6.  Hepatobiliary complications of inflammatory bowel disease.

Authors:  David R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2011-10

Review 7.  Bile acids for primary sclerosing cholangitis.

Authors:  Goran Poropat; Vanja Giljaca; Davor Stimac; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

8.  A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.

Authors:  Gui-Qi Zhu; Ke-Qing Shi; Gui-Qian Huang; Li-Ren Wang; Yi-Qian Lin; Martin Braddock; Yong-Ping Chen; Meng-Tao Zhou; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2015-09-29

Review 9.  Primary sclerosing cholangitis: diagnostic and management challenges.

Authors:  Sanjeev Sirpal; Natasha Chandok
Journal:  Clin Exp Gastroenterol       Date:  2017-11-06

10.  Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.

Authors:  Peter Fickert; Marion J Pollheimer; Dagmar Silbert; Tarek Moustafa; Emina Halilbasic; Elisabeth Krones; Franziska Durchschein; Andrea Thüringer; Gernot Zollner; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2013-01-29       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.